Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody designed to inhibit Wnt pathway signaling. This inhibition is achieved through its specific binding to Frizzled receptors FZD1, FZD2, FZD5, FZD7, and FZD8. The antibody's mechanism of action includes direct effects on tumor cells, including cancer stem cells (CSCs), as well as modulatory effects on the tumor stroma. Vantictumab is primarily researched for its potential therapeutic applications in treating conditions such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody designed to inhibit Wnt pathway signaling. This inhibition is achieved through its specific binding to Frizzled receptors FZD1, FZD2, FZD5, FZD7, and FZD8. The antibody's mechanism of action includes direct effects on tumor cells, including cancer stem cells (CSCs), as well as modulatory effects on the tumor stroma. Vantictumab is primarily researched for its potential therapeutic applications in treating conditions such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
